BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Senexis Limited and Oxygen Healthcare Ltd. Announce Medicinal Chemistry Collaboration


2/14/2008 10:15:50 AM

Cambridge , UK , February 14, 2008: Executives from Senexis and O2H, both located in Cambridge , UK , announced an agreement under which O2H will provide synthetic and computational chemistry services to the drug discovery programmes at Senexis on an FTE basis.

"We believe our collaboration with O2H leverages the complementary expertise of both organisations and will benefit our search for new therapeutics to treat ageing-related diseases by helping Senexis increase the return on its chemistry research budget" said David Scopes, BSc, MSc, PhD - Chief Scientific Officer at Senexis.

Senexis, a recipient of recent Wellcome Trust funding, is a drug development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia, type II diabetes and dialysis related amyloidosis. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of these different diseases. Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Senexis is funded by BTG plc and the Wellcome Trust. Further information on Senexis can be found at www.senexis.com

O2H has its global HQ in the Science Park , Cambridge , UK , project offices in Boston and Tokyo , and a talented team of scientists in its world class discovery research centre in Ahmedabad , India . "Our scientific team in India with our project offices around the world helps our partners to maximise the value of their drug discovery programmes, from initial planning through to lead generation and lead optimisation thereby delivering enormous advantages to our growing portfolio of global clients," says Sunil Shah, CEO, O2H. Further information on O2H can be found at www.oxygenhealthcare.com

OXYGEN HEALTHCARE LTD 23 Cambridge Science Park Cambridge, UK CB4 0EY

SENEXIS LIMITED Babraham Research Campus Babraham, Cambridge , UK CB22 3AT



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES